Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis William L. Baker, PharmD, FCCP, Lindsay R. Smyth, PharmD, Daniel M. Riche, PharmD, Emily M. Bourret, PharmD, Kevin W. Chamberlin, PharmD, William B. White, MD, FASH, FAHA, FACP Journal of the American Society of Hypertension Volume 8, Issue 4, Pages 262-275.e9 (April 2014) DOI: 10.1016/j.jash.2014.01.007 Copyright © 2014 American Society of Hypertension Terms and Conditions
Figure 1 Prisma diagram. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Figure 2 Impact of SGLT2 inhibitors on systolic blood pressure. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Figure 3 Impact of SGLT2 inhibitors on diastolic blood pressure. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Figure 4 Random-effects meta-regression evaluating relationship between canagliflozin dose & mean change in SBP from baseline. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Figure 5 Funnel plot of orthostatic hypotension. The dark circles represent individual studies and the red open circles represent imputed filled studies. The black line represents the base-case treatment effect and the red line is the re-estimate adding the filled studies. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 1 Impact of SGLT2 inhibitors on systolic blood pressure by control. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 2 Impact of SGLT2 inhibitors on systolic blood pressure by drug. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 3 Impact of SGLT2 inhibitors on diastolic blood pressure by control. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 4 Impact of SGLT2 inhibitors on diastolic blood pressure by drug. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 5 Impact of SGLT2 inhibitors on orthostatic hypotension by drug. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 6 Impact of SGLT2 inhibitors on body weight by control. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 7 Impact of SGLT2 inhibitors on body weight by drug. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 8 Impact of SGLT2 inhibitors on hematocrit by control. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions
Supplemental Figure 9 Impact of SGLT2 inhibitors on hematocrit by drug. Journal of the American Society of Hypertension 2014 8, 262-275.e9DOI: (10.1016/j.jash.2014.01.007) Copyright © 2014 American Society of Hypertension Terms and Conditions